Zhejiang Medicine Co Ltd (600216) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin.
Total Cash From Operating Activities Chart for Zhejiang Medicine Co Ltd
Zhejiang Medicine Co Ltd (600216) operating cash flow for FY2025 was CNY 1.9B, a 54.2% change from FY2024. Zhejiang Medicine Co Ltd's operating cash flow grew from CNY 57.7M in 1998 to CNY 1.9B in 2025 (3167.3% over 27 years). Operating cash flow compound annual growth rate: 5-year CAGR of 8.5%, 10-year CAGR of 33.3%, 20-year CAGR of 24.1%.
Total Cash From Operating Activities (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥10.22B
- Implied Share Price
- ¥10.63
- Enterprise Value
- ¥7.37B
- Revenue (TTM)
- ¥8.43B
- EBITDA
- ¥1.32B
- Profit Margin
- 7.51%
- Trailing P/E
- 16.11
- Forward P/E
- 13.39
- Price/Book (MRQ)
- 0.89
- Price/Sales (TTM)
- 1.21
- EV/EBITDA
- 12.39
- EV/Revenue
- 0.87
- Dividend Yield
- 2.64%
- Book Value
- ¥11.84
- Free Cash Flow (FY2025)
- ¥1.44B
- Free Cash Flow Yield
- 14.08%
Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.